KR101098136B1 - 높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 - Google Patents
높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 Download PDFInfo
- Publication number
- KR101098136B1 KR101098136B1 KR1020090082273A KR20090082273A KR101098136B1 KR 101098136 B1 KR101098136 B1 KR 101098136B1 KR 1020090082273 A KR1020090082273 A KR 1020090082273A KR 20090082273 A KR20090082273 A KR 20090082273A KR 101098136 B1 KR101098136 B1 KR 101098136B1
- Authority
- KR
- South Korea
- Prior art keywords
- paramagnetic
- formula
- complex
- gadolinium
- dtpa
- Prior art date
Links
- 230000005298 paramagnetic effect Effects 0.000 title claims abstract description 43
- 239000002616 MRI contrast agent Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims abstract description 49
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000002872 contrast media Substances 0.000 claims abstract description 39
- 229910052751 metal Inorganic materials 0.000 claims abstract description 27
- 239000002184 metal Substances 0.000 claims abstract description 27
- 150000004696 coordination complex Chemical class 0.000 claims abstract description 20
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 18
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 10
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 239000010949 copper Substances 0.000 claims description 21
- 239000011575 calcium Substances 0.000 claims description 17
- 239000011701 zinc Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 abstract description 27
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 14
- 230000005291 magnetic effect Effects 0.000 abstract description 10
- 150000002739 metals Chemical class 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 229960004717 insulin aspart Drugs 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 230000006641 stabilisation Effects 0.000 description 9
- 238000011105 stabilization Methods 0.000 description 9
- 150000000921 Gadolinium Chemical class 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001308 synthesis method Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940039231 contrast media Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- 0 *CC(C(O)=O)NC(CN(CCN(CCN(CC(NC(C*)C(O)=O)=O)CC(O)=O)CC(O)=O)CC(O)=O)=O Chemical compound *CC(C(O)=O)NC(CN(CCN(CCN(CC(NC(C*)C(O)=O)=O)CC(O)=O)CC(O)=O)CC(O)=O)=O 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 238000004639 Schlenk technique Methods 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Equilibrium | L1 | L2 | Omniscan |
[HL]/[L][H] | 9.52 | 11.55 | 9.37 |
[H2L]/[HL][H] | 7.59 | 9.42 | 4.38 |
[H3L]/[H2L][H] | 6.52 | 5.92 | 3.31 |
[H5L]/[H4L][H] | 3.82 | 2.04 | - |
∑pK a | 27.45 | 28.93 | 17.06 |
[GdL]/[Gd][L] | 19.59 | 21.12 | 16.85 |
{log KGdL(pH7.4)} | 17.03 | 14.93 | 14.84 |
[CaL]/[Ca][L] | 6.86 | 10.18 | 7.17 |
{log KCaL(pH7.4)} | 4.30 | 4.01 | 5.11 |
[ZnL]/[Zn][L] | 10.93 | 14.67 | 12.04 |
{log KZnL(pH7.4)} | 8.37 | 8.48 | 10.02 |
[CuL]/[Cu][L] | 10.98 | 14.78 | 13.03 |
{log KCuL(pH7.4)} | 8.42 | 8.59 | 11.06 |
[log Ksel(Gd/Ca)] | 12.73 | 10.92 | 9.68 |
[log Ksel(Gd/Zn)] | 8.66 | 6.45 | 4.81 |
[log Ksel(Gd/Cu)] | 8.66 | 6.34 | 3.82 |
log K'sel | 19.59 | 10.74 | 9.03 |
pGd | 16.03 | 13.98 | 13.88 |
pCa | 3.30 | 30.1 | 4.19 |
pZn | 7.37 | 7.48 | 9.06 |
pCu | 7.42 | 7.59 | 10.05 |
log K (25℃, μ = 0.10M (KCl)) pM = -log[Mn+] free at pH 7.4; [Mn+]total = 1 μmol/dm3; [L]total = 1.1 μmol/dm3 |
Complex | R1(mM-1s-1) | |
L1 | L2 | |
[Gd(L)H2O] | 5.9±0.03 | 6.9±0.04 |
[Gd(L)H2O·Cu2] | 13.0±0.25 | 14.1±0.21 |
[Gd(L)H2O·Zn2] | 5.2±0.26 | 5.6±0.28 |
[Gd(L)H2O·Na2] | 5.5±0.27 | 5.7±0.28 |
[Gd(L)H2O·Mg2] | 5.5±0.27 | 5.7±0.28 |
[Gd(L)H2O·K2] | 5.5±0.27 | 5.6±0.28 |
[Gd(L)H2O·Ca2] | 5.5±0.27 | 5.7±0.28 |
Omniscan | 3.3±0.03 |
Claims (10)
- 제3항에 있어서, 상기 상자성 금속은 나트륨, 칼륨, 마그네슘, 칼슘, 구리 및 아연으로 이루어지는 군에서 선택되는 것을 특징으로 하는 상자성 다핵 금속착물.
- 1) DTPA(DiethyleneTriamine PentaAcetic acid)-비스-안하이드라이드(DTPA-bis-anhydride)에 히스티딘(histidine) 또는 아스파르트산(aspartic acid)을 첨가하여 교반하는 단계(단계 1);2) 상기 단계 1에서 제조된 혼합물의 용매를 모두 제거한 후 메탄올을 넣어 녹인 후 실리카 겔 크로마토그래피를 실시하는 단계(단계 2);3) 상기 단계 2에서 얻어진 화합물을 아세톤에 침전시키는 단계(단계 3); 및4) 상기 단계 3에서 얻어진 물질을 진공상태에서 건조하여 화합물를 얻는 단계(단계 4)를 포함하는, 제1항의 화학식 1로 표시되는 화합물의 제조 방법.
- 1) 제1항의 화학식 1로 표시되는 화합물을 증류수에 넣은 후, Gd2O3를 첨가 하고 교반하여 혼합용액을 제조하는 단계(단계 1);2) 단계 1에서 제조된 혼합용액 중에서 불순물 및 용매를 제거하는 단계(단계2); 및3) 단계 2에서 제조된 물질을 3차 증류수에 녹인 후, 아세톤으로 침전시켜 고체를 수득하는 단계를 포함하는 제2항의 화학식 2로 표시되는 화합물의 가돌리늄 착물의 제조방법.
- 1) 제2항의 화학식 2로 표시되는 화합물의 가돌리늄 착물에 상자성 금속 이온을 첨가하여 혼합용액을 제조하는 단계(단계 1); 및2) 단계 1에서 제조된 혼합용액을 아세톤에 넣어 침전 시킨 후 필터 하여 건조시켜 가돌리늄 착물과 반응하지 않은 상자성 금속 이온을 제거하는 단계(단계 2)를 포함하는 제3항의 화학식 3으로 표시되는 상자성 다핵 금속착물의 제조방법.
- 제7항에 있어서, 상기 상자성 금속은 나트륨, 칼륨, 마그네슘, 칼슘, 구리 및 아연으로 이루어지는 군에서 선택되는 것을 특징으로 하는 상자성 다핵 금속착물.
- 제2항의 화학식 2로 표시되는 가돌리늄 착물을 포함하는 조영제.
- 제3항 또는 제4항의 화학식 3으로 표시되는 상자성 다핵 금속착물을 포함하는 조영제.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090082273A KR101098136B1 (ko) | 2009-09-02 | 2009-09-02 | 높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 |
US13/393,898 US8822697B2 (en) | 2009-09-02 | 2009-11-11 | Paramagnetic polynuclear metal complex having high self-relaxation rate, preparation method thereof, and contrast medium containing same |
PCT/KR2009/006629 WO2011027940A1 (ko) | 2009-09-02 | 2009-11-11 | 높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090082273A KR101098136B1 (ko) | 2009-09-02 | 2009-09-02 | 높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110024333A KR20110024333A (ko) | 2011-03-09 |
KR101098136B1 true KR101098136B1 (ko) | 2011-12-26 |
Family
ID=43649463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090082273A KR101098136B1 (ko) | 2009-09-02 | 2009-09-02 | 높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8822697B2 (ko) |
KR (1) | KR101098136B1 (ko) |
WO (1) | WO2011027940A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105837606A (zh) * | 2016-04-15 | 2016-08-10 | 中国科学院武汉物理与数学研究所 | 一种用作溶液顺磁弛豫增强探针的钆配合物及其合成方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1369134A1 (en) | 2002-06-05 | 2003-12-10 | Bracco Imaging S.p.A. | New agents for magnetic imaging method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5508388A (en) | 1992-07-16 | 1996-04-16 | Mallinckrodt Medical, Inc. | Process for manufacturing DTPA-bis amide magnetic resonance imaging |
DE102005015268A1 (de) | 2005-04-04 | 2006-10-12 | Adc Gmbh | Steckverbindung |
-
2009
- 2009-09-02 KR KR1020090082273A patent/KR101098136B1/ko active IP Right Grant
- 2009-11-11 US US13/393,898 patent/US8822697B2/en not_active Expired - Fee Related
- 2009-11-11 WO PCT/KR2009/006629 patent/WO2011027940A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1369134A1 (en) | 2002-06-05 | 2003-12-10 | Bracco Imaging S.p.A. | New agents for magnetic imaging method |
Non-Patent Citations (2)
Title |
---|
Angew. Chem. Int. Ed. 2008, 47권, 페이지 8568-8580 |
Structure, Dynamics, and Applications. Chem. Rev 1999, 99권, 페이지 2293-2352 |
Also Published As
Publication number | Publication date |
---|---|
US20120226048A1 (en) | 2012-09-06 |
WO2011027940A1 (ko) | 2011-03-10 |
KR20110024333A (ko) | 2011-03-09 |
US8822697B2 (en) | 2014-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2537502B2 (ja) | 1−置換−1,4,7−トリスカルボキシメチル−1,4,7,10−テトラアザシクロドデカンおよび類縁体 | |
KR101236142B1 (ko) | 가돌리늄 착물을 함유하는 mri조영제 | |
US5804163A (en) | Contrast agents for magnetic resonance imaging aminosaccharide | |
EP0430863B1 (de) | Kaskadenpolymer-gebundene Komplexbildner, deren Komplexe und Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
DE69534990T2 (de) | Kontrastmittel | |
JP2667666B2 (ja) | ポリ−(酸−アルキレン−アミノ)−アルカンの常磁性多価金属塩 | |
KR101469900B1 (ko) | Do3a-디아미노바이페닐 화합물 및 이를 리간드로 포함하는 가돌리늄 착물 | |
JPH05503072A (ja) | 診断用nmr映像化の為のヒドロキシ―アリール金属キレート | |
JP3683584B2 (ja) | 樹枝状高分子の金属錯体、これを含有する診断剤、及びこれら錯体及び診断剤の製法 | |
JP2005500387A (ja) | ヒドロキシピリドナート及びヒドロキシピリミジノン系のキレート剤 | |
KR102464647B1 (ko) | 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물 | |
AU2002331348A1 (en) | Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy | |
KR20190091441A (ko) | 다이머 조영제 | |
EP0437438B1 (en) | Contrast agents for magnetic resonance imaging of the small intestine and hepatobiliary system | |
CN109432449B (zh) | 一种铁配合物mri造影剂及其制备方法与应用 | |
KR101098136B1 (ko) | 높은 자기 이완율을 가지는 상자성 다핵금속착물, 이의 제조방법 및 이를 포함하는 조영제 | |
JPH11508550A (ja) | ポリアミノ酸の金属錯体類および診断用イメージングにおけるそれらの使用 | |
JPWO2009157561A1 (ja) | Mri造影能を有する重合体−金属錯体複合体、並びにそれを用いたmri造影用及び/又は抗腫瘍用組成物 | |
BG63105B1 (bg) | Стъпаловидни полимерни комплекси, метод за тяхното получаване и фармацевтични средства, който ги съдържат | |
CA2110815A1 (en) | Novel compositions for magnetic resonance imaging | |
KR100987592B1 (ko) | 암진단용 mr 조영제와 그 제조방법 | |
KR20090123171A (ko) | Dtpa-비스-아미드 리간드를 포함하는 가돌리늄 착물과그 합성방법 | |
JP2008500293A (ja) | 三量体大環状置換アミノイソフタル酸−ハロゲン−ベンゼン誘導体 | |
JP2001504843A (ja) | 大環状金属錯体カルボン酸、その使用並びにその製造法 | |
KR101115799B1 (ko) | Dtpa 유도체, 금속 착물, mr 및 ct 조영제 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141125 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151125 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171110 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181126 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191204 Year of fee payment: 9 |